Navigation Links
Silence Therapeutics Provides Year-end Update
Date:12/21/2010

LONDON, Dec. 21, 2010 /PRNewswire/ -- Silence Therapeutics plc (AIM: SLN) ("Silence" or the "Company"), a leading global biotechnology company dedicated to the discovery, development and delivery of targeted, systemic RNA interference (RNAi) therapeutics for the treatment of serious diseases, today provides a year-end update on trading and the offer-period.

Phil Haworth, CEO of Silence Therapeutics, comments: "2010 has been an exciting year for Silence Therapeutics. The Company is delighted with the clinical progress it has made with Atu027 and our Phase I trial continues on track.  In addition, our partner, Quark Pharmaceuticals, has made significant progress with QPI-1002, both in advancing the product into Phase II trials and in partnering it with Novartis.  We are pleased to be announcing a milestone payment from Quark today."

Offer Period

Further to the announcement dated 6th September 2010, Silence confirms that it remains in an offer period. The Company continues to explore a variety of strategic opportunities.

Atu027 Phase I trial

During the course of 2010, excellent progress has been made with the Company's flagship Phase I trial of Atu027 in patients with solid tumours. This trial remains on track and, to date, 18 patients have been treated. Trial completion is expected in the second half of 2011.

Milestone from Quark

Silence is pleased to announce today that it has reached agreement with Quark Pharmaceuticals Inc. ("Quark") whereby Silence is due to receive milestone payments of up to $1.5 million in relation to the option agreement signed between Quark and Novartis for QPI-1002. Silence anticipates that its share of future milestone payments relating to Quark's license agreement with Novartis could reach $80 million.

  • Based on Silence's AtuRNAi technology, Quark is developing its QPI-1002 for the prevention of acute kidney injury (AKI) in patients undergoing major cardiovascular surgery, and for the prophylaxis of delayed graft function (DGF) in patients receiving deceased donor kidney transplants. Phase I studies in these patient populations have been completed.
  • In September 2010, Quark initiated a Phase II trial of QPI-1002 for the prophylaxis of delayed graft function (DGF) in patients receiving deceased donor kidney transplants.  Quark plans to initiate dosing in a Phase II trial in acute kidney injury (AKI) in 2011.

Notes for editors

About Silence Therapeutics plc (www.silence-therapeutics.com)

Silence Therapeutics plc (AIM: SLN) is a leading global biotechnology company dedicated to the discovery, development and delivery of targeted, systemic RNA interference (RNAi) therapeutics for the treatment of serious diseases. The company possesses multiple proprietary short interfering RNA (siRNA) delivery technology platforms including AtuPLEX™, a system that enables the functional delivery of siRNA molecules to targeted diseased tissues and cells, while increasing their bioavailability and intracellular uptake.  A second, complementary delivery technology known as PolyTran™ uses a library of novel peptide-based biodegradable polycationic polymers for systemic siRNA administration.  Additionally, the company has a platform of novel siRNA molecules, AtuRNAi, which provide a number of advantages over conventional siRNA molecules, including increased stability against nuclease degradation.  Silence's unique RNAi assets also include structural features for a next generation of RNAi molecules and additional proprietary siRNA sequences against more than 50 highly valued oncology and other disease targets.

The company's strong and diverse intellectual property portfolio includes exclusive licenses from the University of Massachusetts Medical School on three patent families associated with the "Zamore Design Rules," which cover broad structural features of siRNA design for more potent next generation siRNA sequences.

Silence Therapeutics is headquartered in London, UK, with research and development activities in Berlin and operations in Redwood City, CA.

Forward-Looking Statements

This press release includes forward-looking statements that are subject to risks, uncertainties and other factors. These risks and uncertainties could cause actual results to differ materially from those referred to in the forward-looking statements. All forward-looking statements are based on information currently available to Silence Therapeutics and Silence Therapeutics assumes no obligation to update any such forward-looking statements.


'/>"/>
SOURCE Silence Therapeutics plc
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Silence Therapeutics Issued New Patents Covering siRNA Sequences for RNA Interference Therapeutics
2. Silence Therapeutics and AstraZeneca Extend siRNA Development Collaboration
3. Silence Therapeutics to Merge with Intradigm Corp to Create Leading RNAi Therapeutics Company
4. Silence Therapeutics to Receive $1.9m Milestone Payment as Pfizer and Quark Commence Phase II Trial
5. Silence Therapeutics Announces Board Changes
6. Recent siRNA Research Publications Support Silence Therapeutics Combined Development Approach
7. Video: Actress and New Mom Keri Russell Joins PKIDs to Launch Silence the Sounds of Pertussis Campaign
8. Actress and New Mom Keri Russell Joins PKIDs to launch Silence the Sounds of Pertussis Campaign
9. Angelica Therapeutics Receives a $244,479 Qualified Therapeutic Discovery Project Grant for Its Anti-Cancer Drug
10. Talecris Biotherapeutics Enrolls Patients in Clinical Trial Evaluating Two Doses of PROLASTIN®-C
11. Osseon® Therapeutics Names Gary Coughlen, CPA as New Chief Financial Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... Story Highlights: ... the health care industry is causing providers to review ... Deloitte offers a suite of solutions for health care ... cost optimization: labor resource analysis, revenue cycle optimization and ... outcomes and better economics ...
(Date:6/24/2016)... Dublin ... of the " Global Markets for Spectroscopy Equipment" ... This report focuses on the global ... including its applications in various applications. The report deals ... three main industries: pharmaceutical and biotechnology, food and beverage, ...
(Date:6/24/2016)... , June 24, 2016 Research and ... Market for Companion Diagnostic Tests" report to their offering. ... for Companion Diagnostics The World Market for ... personalized medicine diagnostics. Market analysis in the report includes the ... Market (In Vitro Diagnostic Kits) by Region (N. America, EU, ...
Breaking Medicine Technology:
(Date:6/26/2016)... North Carolina (PRWEB) , ... June 26, 2016 , ... ... release of a new product that was developed to enhance the health of felines. ... for centuries. , The two main herbs in the PawPaws Cat Kidney Support ...
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs ... College of Mohs Surgery and to Dr. Russell Peckham for medical and surgical dermatology. ... treatment for skin cancer. The selective fellowship in Mohs Micrographic Surgery completed by Dr. ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, Dr. Omkar Marathe ... from the David Geffen School of Medicine at UCLA. He trained in Internal Medicine ... his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published June 14 ... The article goes on to state that individuals are now more comfortable seeking to ... operations such as calf and cheek reduction. The Los Angeles area medical group, Beverly ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Pulmonary ... Dallas that it will receive two significant new grants to support its work ... marked its 25th anniversary by recognizing patients, medical professionals and scientists for their ...
Breaking Medicine News(10 mins):